ZIM Laboratories (NSE:ZIMLAB, BOM:541400) said Portugal's INFARMED has approved its central nervous system drug, dimethyl fumarate 120 mg & 240 mg modified release capsules, according to an Indian bourse filing on Wednesday.
The marketing authorization was granted to ZIM Lab's European subsidiary, SIA ZIM Laboratories. The approval is expected to aid faster clearances in other EU and global markets, the filing said.